Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-cash Items (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Non-cash Items for 11 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items changed N/A year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Dec 2025, changed N/A, and an annual FY2025 reading of $1.5 million, down 72.03% over the prior year.
  • Non-cash Items was $1.5 million for Q4 2025 at Karyopharm Therapeutics, up from $6000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $2.3 million in Q4 2021 and bottomed at $6000.0 in Q4 2022.
  • Average Non-cash Items over 3 years is $1.3 million, with a median of $1.5 million recorded in 2025.
  • The sharpest move saw Non-cash Items tumbled 94.8% in 2021, then plummeted 99.74% in 2022.
  • Year by year, Non-cash Items stood at $2.3 million in 2021, then tumbled by 99.74% to $6000.0 in 2022, then surged by 24900.0% to $1.5 million in 2025.
  • Business Quant data shows Non-cash Items for KPTI at $1.5 million in Q4 2025, $6000.0 in Q4 2022, and $2.3 million in Q4 2021.